In this study, new pyrido [3,4-d] 
Introduction
Tuberculosis (TB) is a chronic and often deadly infectious disease caused by the Mycobacterium tuberculosis. 1 According to the World Health Organization (WHO) Global Tuberculosis Report 2017, in 2016, there were an estimated 1.3 million TB deaths among HIV-negative people and an additional 374.000 deaths among HIV-positive people. 1 Standard TB therapy involves taking isoniazid (INH), rifampicin (RIF), pyrazinamide (PZA) and ethambutol (EMB) for two months (intensive phase), prolong treatment with INH and RIF for four months (continuation phase). 2 In patients with RIF-resistant TB or multidrug-resistant TB, treatment regimens with at least five effective antituberculosis agents during the intensive phase is recommended, including PZA and four group second-line antituberculosis drugs. The regimen may be further strengthened with high dose INH and/or EMB. 3 INH, the first-line drug, is a key component in all TB therapy regimens recommended by the WHO. [1] [2] [3] PZA is also an important first-line drug which has sterilizing activity against semi-dormant tuberculin bacilli. 4 Hence, researchers have modified the INH and PZA scaffolds to develop novel compounds to obtain better antitubercular activity. Additionally, many researchers have worked on hybrid molecules of INH and other antitubercular drugs. [5] [6] [7] [8] [9] [10] [11] [12] Therefore, our group decided to study pyrido [3,4-d] pyridazine ring system which has INH and PZA like scaffold (Figure 1 ). 2,3-Dihydropyrido [3,4-d] pyridazin-1,4-dione (1) and its derivatives are generally synthesized by the reaction of hydrazine hydrate with 3,4-pyridinedicarboxylic acid derivatives, such as 3,4-pyridinedicarboxylic anhydride, 3,4-pyridinedicarbonitriles, dimethyl or diethyl pyridine-3,4-dicarboxylate, 1H-pyrrolo [3,4-c] pyridine-1,3 (2H)-dione. [13] [14] [15] [16] [17] In this study, 3,4-pyridinedicarboxylic acid was used as the starting material and then converted to 3,4-pyridinedicarboxylic anhydride via acetic acid anhydride, followed by the cyclization with hydrazine hydrate. Subsequent to chlorination of pyridazinone ring with phosphorus oxychloride and hydrolysis to monochloro derivatives, the final compounds were obtained via nucleophilic aromatic substitution reaction. Synthesized novel 4-substituted pyrido [3,4-d] pyridazin-1(2H)-one derivatives and 1-substituted pyrido [3,4-d] pyridazin-4(3H)-one derivatives were evaluated for their antimycobacterial, antibacterial, and antifungal properties.
Experimental

1. Chemistry
All chemicals and solvents were purchased locally from Merck AG and Aldrich Chemicals. The microwave reaction was carried out in a MicroSYNTH Microwave Lab station (Milestone S.r.l.). Flash chromatography was performed with a Combi-flashRf automated flash chromatography system with RediSep columns (Teledyne-Isco, Lincoln, NE, USA). Melting points were determined with an Electrothermal-9200 Digital Melting Point Apparatus and are uncorrected. Fourier-transform infrared attenuated total reflectance (FTIR-ATR) spectra were recorded on Perkin Elmer Spectrum 400 FT-IR and FT-NIR spectrometers with a Universal ATR sampler. 1 H NMR spectra were recorded in DMSO-d 6 on a Varian Mercury 400, 400 MHz High Performance Digital FT-NMR spectrometer at the NMR facility of the Faculty of Pharmacy, Ankara University. All chemical shifts were recorded as δ (ppm). Microanalyses for C, H, and N were performed on a Leco-932 at the Faculty of Pharmacy, Ankara University, Ankara, Turkey, and they were within the range of ±0.4% of the theoretical value. HRMS spectra were taken on a Waters LCT Premier XE orthogonal acceleration time-of-flight (oa-TOF) mass spectrometer using ESI (+) or ESI (-) methods (Waters Corporation, Milford, MA, USA). The syntheses of 2,3-dihydropyrido [3,4-d] pyridazin-1,4-dione (compound 1), 13 1,4-dichloropyrido [3,4-d] pyridazine (compound 2), 13 4-chloropyrido [3,4-d] pyridazin-1(2H)-one (compound 3), 13 
1,4-Dichloropyrido[3,4-d]pyridazine (2)
A mixture of 6.52 g (0.04 mol) 2,3-dihydropyrido [3,4-d] pyridazin-1,4-dione and 18.6 mL (0.19 mol) phosphorus oxychloride in 6.46 mL (0.08 mol) pyridine was heated to reflux and stirred for 5 h. The mixture then was poured into a slush of 200 g of ice and then neutralized with NaHCO 3 and then extracted with 3 × 100 mL ethyl acetate. Organic phase was separated, washed with water, dried with Na 2 SO 4 and evaporated to dryness (yield 45%). 1,4-Dichloropyrido[3,4-d]pyridazine was subsequently used without further purification.
4-Chloropyrido[3,4-d]pyridazin-1(2H)-one (3) and 1-Chloropyrido[3,4-d]pyridazin-4(3H)-one (4)
1,4-Dichloropyrido[3,4-d]pyridazine (5 g, 0.025 mol) was heated up to reflux temperature in 150 mL diluted HCl (1%) for 2 h. After cooling, the precipitate formed was filtered off, dried and crystallized from acetic acid to obtain 4-chloropyrido [3,4-d] pyridazin-1(2H)-one with yield of 52%. The remaining reaction medium was neutralized with ammonium hydroxide to precipitate the 1-chloropyrido [3,4-d] pyridazin-4(3H)-one, which was isolated by filtration, washed with water, dried and crystallized from water (yield 34%).
4-Chloropyrido[3,4-d]pyridazin-1(2H)-one (3)
Crystallized from acetic acid to yield 52%; mp 236 °C; FTIR-ATR: 3220-2400 (N-H), 1678 (C=O) cm -1 ; 1 
1-Chloropyrido[3,4-d]pyridazin-4(3H)-one (4)
Crystallized from water to yield 34%; mp 172 °C; FTIR-ATR: 3400-2400 (N-H), 1682 (C=O) cm 4 , and evaporated to dryness and the crude product thus obtained was purified by flash chromatography.
4-(4-Methylpiperazin-1-yl)pyrido[3,4-d]pyridazin-1(2H) -one (5)
Reaction time: 120 min. The crude product was purified by column chromatography using dichloromethane-methanol gradient system. 
4-(4-Benzylpiperazin-1-yl)pyrido[3,4-d]pyridazin-1(2H) -one (6)
Reaction time: 60 min. The crude product was purified by column chromatography using dichloromethane-methanol gradient system. The collected product was crystallized from ethanol to yield 23.75%; mp 245 °C; FTIR-ATR: 3200-2700 (N-H) 
4-(4-Methylpiperidin-1-yl)pyrido[3,4-d]pyridazin-1(2H) -one (7)
Reaction time: 60 min. The crude product was purified by column chromatography using ethyl acetate. The collected product was crystallized from ethanol to yield 40.93%; mp 218 °C; FTIR-ATR: 3300-2700 (N-H) 
4-(4-Benzylpiperidin-1-yl)pyrido[3,4-d]pyridazin-1(2H) -one (8)
Reaction time: 30 min. The crude product was purified by column chromatography using n-hexane-ethyl acetate gradient system. The collected product was crystallized from ethanol to yield 18.42%; mp 225 °C; FTIR-ATR: 3300-2700 (N-H) 
1-(4-Methylpiperazin-1-yl)pyrido[3,4-d]pyridazin-4(3H) -one (9)
Reaction time: 60 min. The crude product was purified by column chromatography using dichloromethane-methanol gradient system. The collected product was crystallized from ethanol to yield 20.38%; mp 206 °C; FTIR-ATR: 3300-2600 (N-H), 1670 (C=O) cm -1 ; 1 
1-(4-Benzylpiperazin-1-yl)pyrido[3,4-d]pyridazin-4(3H)-one (10)
Reaction time: 30 min. The crude product was purified by column chromatography using n-hexane-ethyl acetate gradient system. The collected product was crystallized from ethanol to yield 45.13%; mp 230 °C; FTIR-ATR: 3200-2300 (N-H) 
1-(4-Methylpiperidin-1-yl)pyrido[3,4-d]pyridazin-4(3H) -one (11)
Reaction time: 45 min. The crude product was purified by column chromatography using n-hexane-ethyl ac- 
1-(4-Benzylpiperidin-1-yl)pyrido[3,4-d]pyridazin-4(3H)-one (12)
Reaction time: 30 min. The crude product was purified by column chromatography using n-hexane-ethyl acetate gradient system. The collected product was crystal- 
Biological Activity
1. Antibacterial and Antifungal Activity 18,19
Microorganisms
Standard strains of Escherichia coli ATCC 35218, Pseudomonas aeruginosa ATCC 10145, Staphylococcus aureus ATCC 6538, Enterococcus faecalis ATCC 29212, Candida albicans ATCC 10231 and clinical isolates from Trakya University Health Center for Medical Research and Practice Microbiology Laboratory were included in the study.
Microdilution Method
Mueller Hinton Agar (MHA), Mueller Hinton Broth (MHB), Sabouraud Dextrose Agar (SDA), Sabouraud Liquid Medium (SLM) and RPMI-1640 medium with L-glutamine (Sigma) buffered with MOPS (Sigma) (pH 7) were used in the study. MHA, MHB, SDA and SLM were sterilized with autoclave at 121 °C for 15-20 minutes and RPMI-1640 was sterilized by filtration. Susceptibility testing was performed according to the guidelines of Clinical and Laboratory Standards Institute (CLSI) M100-S18 and M27-A3. 100 µL of MHB and RPMI-1640 medium with L-glutamine (Sigma) buffered with MOPS (pH 7) were added to each well of the microplates for bacteria and fungi, respectively. The bacterial suspensions used for inoculation were prepared at 10 5 CFU/mL by diluting fresh cultures at McFarland 0.5 density. Suspensions of the yeast at McFarland density was diluted 1:100 and 1:20 respectively and 2.5·10 3 CFU/mL were inoculated to the two fold-diluted solutions of the compounds. Stock solutions of the tested compounds were dissolved in DMSO. Standard antibiotic solutions were dissolved in appropriate solvents recommended by CLSI guidelines. Stock solutions of the tested compounds and standard drugs were diluted two-fold in the wells of the microplates so the solution of the synthesized compounds and standard drugs were prepared at 1024, 512, 256, 128, 64, 32, 16, 8, 4, 2, 1, 0.5 µg/mL and standard drugs were prepared at 64, 32, 16, 8, 4, 2, 1, 0.5, 0.25, 0.125, 0.0625, 0.03125 µg/mL concentrations. All solvents and diluents, pure microorganisms and pure media were used in control wells. A 10 µL microorganisms inoculum was added to each well of the microplates. Microplates including bacteria were incubated at 37 °C for 16-20 hours and microplates including fungi were incubated at 35 °C for 24-48 hours. After incubation, the lowest concentration of the compounds that completely inhibits macroscopic growth was determined and reported as minimum inhibitory concentrations (MICs).
Antimycobacterial Activity 20,21
Agar Proportion Method
The minimum inhibitory concentration (MIC) values of each synthesized compound were tested by agar dilution in duplicate as recommended by the Clinical Laboratory Standards Institute (CLSI). 20, 21 Positive and negative growth controls were run in each assay. Isoniazid (INH) (Sigma I3377) and rifampicin (RIF) (Sigma R3501) were used as control agents. M. tuberculosis H37Rv was used as the standard strain and was provided by Refik Saydam National Public Health Agency, National Tuberculosis Reference Laboratory, Ankara, Turkey. Stock solutions of synthesized compounds and reference compounds were prepared in DMSO/H 2 O (50%) at a concentration of 1000 μg/mL. These solutions were then filtered through a 0.22 μm membrane filter (Millipore, USA). Middlebrook 7H10 agar medium (BBL, Becton Dickinson and Company, Sparks, MD, USA) was supplemented with oleic acid-albumin-dextrose-catalase (OADC, BBL, Becton Dickinson and Company, Sparks, MD, USA). Synthesized compounds and control agents were added to obtain an appropriate final concentration in the medium. The final concentrations of INH and RIF were 0.2-1 μg/mL and 1 μg/mL, respectively. Synthesized compounds were prepared at final concentrations of 5, 10, 20, 40 and 80 μg/mL. Agar without any references and synthesized compounds were used as a positive growth control, and 3 mL of prepared medium was dispensed into sterile tubes. The DMSO concentration in the final solutions was not above 1% for antimycobacterial activity.
Inoculum Preparation
H37Rv was maintained in Lowenstein-Jensen medium. A culture suspension was prepared by subculturing in Middlebrook 7H9 broth (BBL, Becton Dickinson and Company, Sparks, MD, USA) supplemented with 10% OADC at 37 °C for 7-10 days, until a density corresponding to 10 -2 to 10 -4 dilutions were obtained from McFarland standard No. 1. Then 0.1 mL of the diluted suspension was inoculated onto the control and the other tubes with compounds in different concentrations. The tubes were incubated at 37 °C in an atmosphere of 5% CO 2 for 3 weeks.
The MIC values were defined as the lowest concentration that inhibited more than 90% of the bacterial growth and the results of INH and RIF were interpreted according to the CLSI. The MIC was considered the lowest concentration that showed no visible colonies in all dilutions.
Result and Discussion
The synthetic routes for the synthesized compounds are outlined in Scheme 1. The starting compound 2,3-dihydropyrido [3,4-d] pyridazin-1,4-dione (1) was readily prepared by the reaction of 3,4-pyridinedicarboxylic acid Scheme 1. Reagents and conditions: (i) acetic acid anhydride, reflux, 1 h; (ii) hydrazine hydrate, reflux, 4 h; (iii) phosphorus oxychloride, pyridine, reflux, 5 h; (iv) dil. HCl, reflux, 2 h; (v) dil. HCl, reflux, 2 h, neutralized with NH 4 OH; (vi) appropriate piperazine or piperidine derivatives, diethylene glycol, and heat under MW. X = N, C; R: methyl, benzyl. 
